Novartis buys dry eye drug from Takeda for up to $5.3 billion

Novartis is buying dry-eye drug Xiidra from Takeda Pharmaceutical Co for up to $5.3 billion as the Swiss drugmaker refreshes its ophthalmic medicines portfolio with a potential blockbuster.

from Reuters: Business News https://reut.rs/2ZZk5L0